Recce Pharmaceuticals Ltd
ASX:RCE
Recce Pharmaceuticals Ltd
Revenue
Recce Pharmaceuticals Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Revenue
AU$6.8m
|
CAGR 3-Years
104%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$190.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$237.6m
|
CAGR 3-Years
550%
|
CAGR 5-Years
77%
|
CAGR 10-Years
47%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Revenue
AU$588.4k
|
CAGR 3-Years
56%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Probiotec Ltd
ASX:PBP
|
Revenue
AU$221.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Revenue
AU$11.7m
|
CAGR 3-Years
59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Recce Pharmaceuticals Ltd's Revenue?
Revenue
6.8m
AUD
Based on the financial report for Dec 31, 2023, Recce Pharmaceuticals Ltd's Revenue amounts to 6.8m AUD.
What is Recce Pharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 5Y
34%
Over the last year, the Revenue growth was 115%. The average annual Revenue growth rates for Recce Pharmaceuticals Ltd have been 104% over the past three years , 34% over the past five years .